927 related articles for article (PubMed ID: 32321665)
1. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
2. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
[TBL] [Abstract][Full Text] [Related]
3. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of preoperative prognostic factors in patients with resectable invasive intraductal papillary mucinous carcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Surgery; 2020 Dec; 168(6):994-1002. PubMed ID: 32139141
[TBL] [Abstract][Full Text] [Related]
5. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
[TBL] [Abstract][Full Text] [Related]
6. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
7. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
8. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
9. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
10. Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection.
Hosokawa Y; Nagakawa Y; Sahara Y; Takishita C; Katsumata K; Tsuchida A
Dig Surg; 2017; 34(2):125-132. PubMed ID: 27658221
[TBL] [Abstract][Full Text] [Related]
11. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
[TBL] [Abstract][Full Text] [Related]
12. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.
Groot VP; Gemenetzis G; Blair AB; Rivero-Soto RJ; Yu J; Javed AA; Burkhart RA; Rinkes IHMB; Molenaar IQ; Cameron JL; Weiss MJ; Wolfgang CL; He J
Ann Surg; 2019 Jun; 269(6):1154-1162. PubMed ID: 31082915
[TBL] [Abstract][Full Text] [Related]
13. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection.
Sugawara T; Ban D; Nishino J; Watanabe S; Maekawa A; Ishikawa Y; Akahoshi K; Ogawa K; Ono H; Kudo A; Tanaka S; Tanabe M
PLoS One; 2021; 16(4):e0249885. PubMed ID: 33844700
[TBL] [Abstract][Full Text] [Related]
14. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
Barnes CA; Aldakkak M; Christians KK; Clarke CN; Dua K; George B; Ritch PS; Kamgar M; Hall WA; Kulkarni N; Erickson BA; Evans DB; Tsai S
Surgery; 2020 Sep; 168(3):440-447. PubMed ID: 32641278
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
[TBL] [Abstract][Full Text] [Related]
16. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
[TBL] [Abstract][Full Text] [Related]
17. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
18. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection.
Shirai Y; Shiba H; Sakamoto T; Horiuchi T; Haruki K; Fujiwara Y; Futagawa Y; Ohashi T; Yanaga K
Surgery; 2015 Aug; 158(2):360-5. PubMed ID: 26032829
[TBL] [Abstract][Full Text] [Related]
19. The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvant therapy.
Suto H; Okano K; Oshima M; Ando Y; Takahashi S; Shibata T; Kamada H; Kobara H; Masaki T; Suzuki Y
BMC Surg; 2019 Dec; 19(1):186. PubMed ID: 31796066
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant therapy versus upfront resection for clinically "resectable" pancreatic cancer: The debate continues.
Sarr MG; Behrns KE
Surgery; 2020 Dec; 168(6):993. PubMed ID: 33066983
[No Abstract] [Full Text] [Related]
[Next] [New Search]